CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.05
-0.07 (-1.37%)
At close: Dec 12, 2025, 4:00 PM EST
5.29
+0.24 (4.75%)
After-hours: Dec 12, 2025, 6:48 PM EST
CureVac Revenue
CureVac had revenue of 54.13M EUR in the quarter ending September 30, 2025, a decrease of -89.04%. This brings the company's revenue in the last twelve months to 70.74M, down -86.98% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
70.74M EUR
Revenue Growth
-86.98%
P/S Ratio
9.77
Revenue / Employee
71,964 EUR
Employees
983
Market Cap
1.14B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 535.18M | 481.42M | 895.54% |
| Dec 31, 2023 | 53.76M | -13.66M | -20.26% |
| Dec 31, 2022 | 67.42M | -35.57M | -34.54% |
| Dec 31, 2021 | 102.99M | 54.12M | 110.74% |
| Dec 31, 2020 | 48.87M | 31.46M | 180.61% |
| Dec 31, 2019 | 17.42M | 4.55M | 35.31% |
| Dec 31, 2018 | 12.87M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CVAC News
- 10 days ago - BioNTech Achieves Minimum Condition in CureVac Exchange Offer - GlobeNewsWire
- 15 days ago - CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 17 days ago - CureVac Announces Voting Results of Extraordinary General Meeting - Accesswire
- 19 days ago - CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates - Accesswire
- 2 months ago - CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha
- 4 months ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Accesswire
- 4 months ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 6 months ago - CureVac Announces Voting Results of General Meeting - Accesswire